Patent number: 11040957
Abstract: The present invention provides novel compounds of Formula (I), and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are methods and kits involving the compounds or compositions for treating or preventing proliferative diseases (e.g., cancers (e.g., leukemia, melanoma, multiple myeloma), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject. Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit the aberrant activity of a kinase, such as a cyclin-dependent kinase (CDK) (e.g., cyclin-dependent kinase 7 (CDK7)), and therefore, induce cellular apoptosis and/or inhibit transcription in the subject.
Type:
Grant
Filed:
December 5, 2018
Date of Patent:
June 22, 2021
Assignees:
Dana-Farber Cancer Institute, Inc., Syros Pharmaceuticals, Inc.
Inventors:
Stephane Ciblat, Patrick Deroy, Nathanael Gray, Melissa Leblanc, Jason J. Marineau, Joel Moore, Kevin Sprott, Tinghu Zhang, M. Arshad Siddiqui, Anzhelika Kabro, Serge Leger, Stephanie Roy, Darby Schmidt, Dana K. Winter, Michael Bradley, Tom Miller
Patent number: 10882834
Abstract: A compound, or a pharmaceutically acceptable salt or ester thereof, having a formula I of: R20—(Z)b—(Y)c—(R21)a—X—R22—R23 wherein R20 is an aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycloalkyl, substituted heterocycloalkyl, alkoxy, aryloxy, a silyl-containing group, a boryl-containing group, a phosphine-containing group, amino, a thio-containing group, a seleno-containing group, halide, or a nitro-containing group; Z is alkanediyl, substituted alkanediyl, cycloalkanediyl, or substituted cycloalkanediyl; Y is S, O, or NR10, wherein R10 is H or alkyl; R21 is alkanediyl, substituted alkanediyl, cycloalkanediyl, substituted cycloalkanediyl, alkadienyl, substituted alkadienyl, alkatrienyl, substituted alkatrienyl; X is —C(=0)- or —S(=0)(=0)-; R22 is a moiety that includes at least one divalent amino radical; R23 is an aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycloalkyl, substituted heterocycloalkyl, alkoxy, aryloxy, a silyl-containing group, a boryl-containing group
Type:
Grant
Filed:
September 18, 2014
Date of Patent:
January 5, 2021
Assignee:
University of Pittsburgh—Of the Commonwealth System of Higher Education
Inventors:
Peter Wipf, Erin M. Skoda, Zhou Wang
Patent number: 10874636
Abstract: Disclosed is an application of substituted cinnamamide derivatives in the preparation of anti-anxiety medications, the substituted cinnammide derivatives are compounds having the structure of formula (I) or pharmaceutically acceptable salts thereof, wherein, R1 is —H, —OH, —F, —Cl, —Br, —I, —OCH3, —OCF3, —OCHF2, —OCH2F, —CF3, —CHF2, —CH2F, —CH3, —CH3CH2, —CF3CH2, —CN, —NO2, —NH2 or —COOR5; R2 is H, C1-C10 linear alkyl, C3-C10 branched alkyl, C3-C10 cyclic alkyl, C1-C10 hydroxyalkyl or a N-substituted piperazine-derived group; or R2 is a group forming with adjacent Y a tetrahydropyrrolyl group, a piperidyl group or a cyclohexanimido group.
Type:
Grant
Filed:
January 20, 2017
Date of Patent:
December 29, 2020
Assignee:
Tasly Pharmaceutical Group Co., Ltd.
Inventors:
Min Han, Xiaohui Ma, Wangyi Zhou, Yanyong Liu, Yanchuan Li, Jing Wang, Shuiping Zhou, He Sun, Yonghong Zhu